Brean Murray Issues Mid-Day Upgrade on Vertex Pharma (VRTX)

Article Stock Quotes (1) Comments (0)

Brean Murray Carret & Co.'s Brian Skorney upgraded shares of Vertex (NASDAQ: VRTX) in an afternoon research report Monday. The upgrade follows positive trial results from a study on VX-809 and KALYDECO. Shares of Vertex have surged more than 55 percent amid the news.

Skorney said, "Vertex put lackluster Phase 2 results from last summer in the rearview mirror today by demonstrating profound clinical benefits in a subset of cystic fibrosis patients. We believe these results have the potential to expand the company's targeted CF population by 10x. Although Phase 3 still remains a hurdle, we now have confidence that the robust sales numbers seen in the first quarter of Kalydeco sales will be possible across a much larger patient population..."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
• UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines

Create E-mail Alert Related Categories

Upgrades

Related Entities

Brean Murray Carret & Co.

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?